SG11201401330YA - Treatment of multiple sclerosis with combination of laquinimod and fingolimod - Google Patents
Treatment of multiple sclerosis with combination of laquinimod and fingolimodInfo
- Publication number
- SG11201401330YA SG11201401330YA SG11201401330YA SG11201401330YA SG11201401330YA SG 11201401330Y A SG11201401330Y A SG 11201401330YA SG 11201401330Y A SG11201401330Y A SG 11201401330YA SG 11201401330Y A SG11201401330Y A SG 11201401330YA SG 11201401330Y A SG11201401330Y A SG 11201401330YA
- Authority
- SG
- Singapore
- Prior art keywords
- laquinimod
- fingolimod
- treatment
- combination
- multiple sclerosis
- Prior art date
Links
- KKGQTZUTZRNORY-UHFFFAOYSA-N fingolimod Chemical compound CCCCCCCCC1=CC=C(CCC(N)(CO)CO)C=C1 KKGQTZUTZRNORY-UHFFFAOYSA-N 0.000 title 1
- 229960000556 fingolimod Drugs 0.000 title 1
- GKWPCEFFIHSJOE-UHFFFAOYSA-N laquinimod Chemical compound OC=1C2=C(Cl)C=CC=C2N(C)C(=O)C=1C(=O)N(CC)C1=CC=CC=C1 GKWPCEFFIHSJOE-UHFFFAOYSA-N 0.000 title 1
- 229960004577 laquinimod Drugs 0.000 title 1
- 201000006417 multiple sclerosis Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
- A61J1/03—Containers specially adapted for medical or pharmaceutical purposes for pills or tablets
- A61J1/035—Blister-type containers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Emergency Medicine (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Inorganic Chemistry (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Psychiatry (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161546102P | 2011-10-12 | 2011-10-12 | |
| PCT/US2012/059733 WO2013055907A1 (en) | 2011-10-12 | 2012-10-11 | Treatment of multiple sclerosis with combination of laquinimod and fingolimod |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201401330YA true SG11201401330YA (en) | 2014-05-29 |
Family
ID=48082429
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201401330YA SG11201401330YA (en) | 2011-10-12 | 2012-10-11 | Treatment of multiple sclerosis with combination of laquinimod and fingolimod |
Country Status (18)
| Country | Link |
|---|---|
| US (4) | US8889627B2 (enExample) |
| EP (1) | EP2766020A4 (enExample) |
| JP (2) | JP2014530821A (enExample) |
| KR (1) | KR20140101333A (enExample) |
| CN (2) | CN103974704A (enExample) |
| AR (1) | AR088458A1 (enExample) |
| AU (2) | AU2012322706A1 (enExample) |
| BR (1) | BR112014008731A2 (enExample) |
| CA (1) | CA2851525A1 (enExample) |
| EA (1) | EA201490748A1 (enExample) |
| HK (1) | HK1199820A1 (enExample) |
| IL (1) | IL231724A0 (enExample) |
| MX (1) | MX2014004420A (enExample) |
| SG (1) | SG11201401330YA (enExample) |
| TW (1) | TW201321001A (enExample) |
| UY (1) | UY34395A (enExample) |
| WO (1) | WO2013055907A1 (enExample) |
| ZA (1) | ZA201403378B (enExample) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009082471A1 (en) | 2007-12-20 | 2009-07-02 | Teva Pharmaceutical Industries, Ltd. | Stable laquinimod preparations |
| WO2011019375A1 (en) * | 2009-08-10 | 2011-02-17 | Teva Pharmaceutical Industries Ltd. | Treatment of bdnf-related disorders using laquinimod |
| AU2010302350B2 (en) | 2009-10-02 | 2015-06-18 | Journey Medical Corporation | Surfactant-free water-free foamable compositions, breakable foams and gels and their uses |
| HUE036391T2 (hu) | 2009-11-13 | 2018-07-30 | Celgene Int Ii Sarl | Szfingozin 1 foszfát receptor modulátorok és királis szintézis eljárások |
| PL2498610T5 (pl) | 2009-11-13 | 2024-11-04 | Receptos Llc | Selektywne modulatory receptora sfingozyno-1-fosforanu i sposoby syntezy chiralnej |
| US12661407B2 (en) | 2010-04-08 | 2026-06-23 | Journey Medical Corporation | Compositions, gels and foams with rheology modulators and uses thereof |
| US9481659B2 (en) | 2011-05-13 | 2016-11-01 | Celgene International Ii Sàrl | Selective heterocyclic sphingosine 1 phosphate receptor modulators |
| SG11201401330YA (en) * | 2011-10-12 | 2014-05-29 | Teva Pharma | Treatment of multiple sclerosis with combination of laquinimod and fingolimod |
| CN104245717B (zh) * | 2011-12-28 | 2017-10-24 | 卡莱克汀医疗有限公司 | 用于治疗人类疾病的新型糖类药物的组合物 |
| WO2013116657A1 (en) | 2012-02-03 | 2013-08-08 | Teva Pharmaceutical Industries Ltd. | USE OF LAQUINIMOD FOR TREATING CROHN'S DISEASE PATIENTS WHO FAILED FIRST-LINE ANTI-TNFα THERAPY |
| MX2014009889A (es) | 2012-02-16 | 2014-11-13 | Teva Pharma | N-etil-n-fenil-1,2-dihidro-4,5-di-hidroxi-1-metil-2-oxo-3-quinoli ncarboxamida, preparacion y usos de los mismos. |
| TW201804997A (zh) * | 2012-05-02 | 2018-02-16 | 以色列商泰瓦藥品工業有限公司 | 高劑量拉喹莫德(laquinimod)於治療多發性硬化症之用途 |
| TW201350467A (zh) | 2012-05-08 | 2013-12-16 | Teva Pharma | Ｎ－乙基－４－羥基－１－甲基－５－（甲基（２，３，４，５，６－五羥基己基）胺基）－２－側氧－ｎ－苯基－１，２－二氫喹啉－３－甲醯胺 |
| TW201400117A (zh) | 2012-06-05 | 2014-01-01 | Teva Pharma | 使用拉喹莫德治療眼發炎疾病 |
| UY34896A (es) * | 2012-07-12 | 2014-02-28 | Teva Pharma | Tratamiento de la esclerosis múltiple con una combinación de laquinimod y fampridina |
| TW201410244A (zh) | 2012-08-13 | 2014-03-16 | Teva Pharma | 用於治療ｇａｂａ媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ） |
| MX2015004564A (es) * | 2012-10-12 | 2015-07-21 | Teva Pharma | Laquinimod para producir el daño talamico en la esclerosis multiple. |
| EA201590788A1 (ru) | 2012-11-07 | 2015-12-30 | Тева Фармасьютикал Индастриз Лтд. | Аминные соли лахинимода |
| JP2016514162A (ja) | 2013-03-14 | 2016-05-19 | テバ ファーマシューティカル インダストリーズ リミティド | ラキニモドナトリウムの結晶およびその製造のための改善された方法 |
| JP2016527270A (ja) * | 2013-07-31 | 2016-09-08 | テバ ファーマシューティカル インダストリーズ リミティド | ラキニモドおよびフルピルチンの組合せによる多発性硬化症の治療 |
| WO2015066515A1 (en) * | 2013-11-01 | 2015-05-07 | Receptos, Inc. | Selective sphingosine 1 phosphate receptor modulators and combination therapy therewith |
| BR112016014507A2 (pt) * | 2013-12-20 | 2018-05-22 | Teva Pharma | uso de laquinimod para retardar progressão da doença de huntington |
| AR098924A1 (es) * | 2013-12-23 | 2016-06-22 | Teva Pharma | Tratamiento de la esclerosis múltiple con una combinación de laquinimod y teriflunomida |
| HK1231413A1 (zh) | 2014-04-29 | 2017-12-22 | Teva Pharmaceutical Industries Ltd. | 用於治疗具有高残疾状况的复发-缓解型多发性硬化症(rrms)的患者的拉喹莫德 |
| WO2016044103A1 (en) * | 2014-09-16 | 2016-03-24 | Teva Pharmaceutical Industries Ltd. | Treatment of neurodegenerative diseases with combination of laquinimod and fingolimod |
| CA2964315A1 (en) | 2014-10-16 | 2016-04-21 | Novartis Ag | Combinations comprising siponimod and laquinimod for the treatment of multiple sclerosis |
| WO2016075543A1 (en) * | 2014-11-13 | 2016-05-19 | Teva Pharmaceutical Industries Ltd. | Treatment of multiple sclerosis with combination of laquinimod and a phosphodiesterase-4 (pde4) inhibitor |
| US20180036302A1 (en) * | 2014-12-10 | 2018-02-08 | Teva Pharmaceutical Industries Ltd. | Treatment of multiple sclerosis with combination of laquinimod and a statin |
| GB2540163A (en) * | 2015-07-07 | 2017-01-11 | Univ London Queen Mary | Combination therapy for treating multiple sclerosis |
| MX2020012139A (es) | 2016-09-08 | 2021-01-29 | Vyne Pharmaceuticals Inc | Composiciones y metodos para tratar rosacea y acne. |
| WO2019245513A2 (en) * | 2018-06-21 | 2019-12-26 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | A combination comprising fingolimod and amantadine |
| WO2021158841A1 (en) * | 2020-02-07 | 2021-08-12 | Argentum Pharmaceuticals Llc | Treatment and dosing regimen for s1p receptor modulator |
| WO2021158847A1 (en) * | 2020-02-07 | 2021-08-12 | Argentum Pharmaceuticals Llc | Treatment and dosing regimen for s1p receptor modulator |
| WO2021158845A1 (en) * | 2020-02-07 | 2021-08-12 | Argentum Pharmaceuticals Llc | Treatment and dosing regimen for s1p receptor modulator |
| US11135197B2 (en) | 2020-02-07 | 2021-10-05 | Argentum Pharmaceuticals Llc | Dosage regimen of an S1P receptor modulator |
| WO2021158844A1 (en) * | 2020-02-07 | 2021-08-12 | Argentum Pharmaceuticals Llc | Treatment and dosing regimen for s1p receptor modulator |
| US20240325393A1 (en) * | 2020-08-17 | 2024-10-03 | Vyne Therapeutics Inc. | Tofacitinib-containing anhydrous elastomer-based gel formulations |
| US20240043499A1 (en) | 2022-08-07 | 2024-02-08 | Protean Bio, Inc. | Peptides for beta-cell survival and insulin production |
| CN120173888B (zh) * | 2025-03-26 | 2025-12-30 | 广州通识医学研究有限公司 | 一种基因修饰的人骨髓间充质干细胞的制备方法及其在治疗神经系统疾病的应用 |
Family Cites Families (83)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3024257A (en) | 1961-04-10 | 1962-03-06 | Frosst & Co Charles E | Stable preparations of alkali metal salts of estrone sulfate |
| FR2340735A1 (fr) | 1976-02-11 | 1977-09-09 | Roussel Uclaf | Nouveaux derives de l'acide 3-quinoleine carboxylique, leur procede de preparation et leur application comme medicament |
| IE52670B1 (en) | 1981-03-03 | 1988-01-20 | Leo Ab | Heterocyclic carboxamides,compositions containing such compounds,and processes for their preparation |
| DE3437232A1 (de) | 1984-10-10 | 1986-04-17 | Mack Chem Pharm | Stabilisierte injektionsloesungen von piroxicam |
| US4782155A (en) | 1986-03-19 | 1988-11-01 | Banyu Pharmaceutical Co., Ltd. | Cephalosporin derivatives, processes for their preparation and antibacterial agents |
| US5139878A (en) | 1991-08-12 | 1992-08-18 | Allied-Signal Inc. | Multilayer film constructions |
| KR0155015B1 (ko) * | 1992-10-21 | 1998-12-01 | 고우야 마사시 | 2-아미노-1,3-프로판디올 화합물 및 면역 억제제 |
| US5540934A (en) | 1994-06-22 | 1996-07-30 | Touitou; Elka | Compositions for applying active substances to or through the skin |
| US5912349A (en) | 1997-01-31 | 1999-06-15 | Pharmacia & Upjohn Company | Process for the preparation of roquinimex |
| US20030124187A1 (en) | 1997-02-14 | 2003-07-03 | Smithkline Beecham Laboratoires Pharmaceutiques, | Pharmaceutical formulations comprising amoxycillin and clavulanate |
| US6696407B1 (en) | 1997-03-21 | 2004-02-24 | The Regents Of The University Of California | Huntington's disease treatment comprising administering aldose reductase inhibitors to increase striatal CNTF |
| GB9726339D0 (en) | 1997-12-13 | 1998-02-11 | Zeneca Ltd | Human-derived tissue-specific potassium channel |
| US6077851A (en) | 1998-04-27 | 2000-06-20 | Active Biotech Ab | Quinoline derivatives |
| SE9801474D0 (sv) | 1998-04-27 | 1998-04-27 | Active Biotech Ab | Quinoline Derivatives |
| US6121287A (en) | 1998-07-15 | 2000-09-19 | Active Biotech Ab | Quinoline derivatives |
| SE9802550D0 (sv) | 1998-07-15 | 1998-07-15 | Active Biotech Ab | Quinoline derivatives |
| US6133285A (en) | 1998-07-15 | 2000-10-17 | Active Biotech Ab | Quinoline derivatives |
| SE9802549D0 (sv) | 1998-07-15 | 1998-07-15 | Active Biotech Ab | Quinoline derivatives |
| PL199781B1 (pl) | 1999-10-25 | 2008-10-31 | Active Biotech Ab | Nowe związki pochodne chinoliny, zastosowanie związków pochodnych chinoliny, zawierające je kompozycje farmaceutyczne i sposób ich wytwarzania |
| US6852323B2 (en) | 2000-07-21 | 2005-02-08 | The Regents Of The University Of California | Methods and compositions for preventing and treating male erectile dysfunction and female sexual arousal disorder |
| US6307050B1 (en) | 2000-08-29 | 2001-10-23 | R. T. Alamo Venture I Llc | Method of synthesizing flosequinan from 4-fluoroanthranilic acid |
| US6802422B2 (en) | 2000-12-12 | 2004-10-12 | Multi-Comp, Inc. | Sealed blister assembly |
| US6706733B2 (en) | 2001-05-08 | 2004-03-16 | Dainippon Ink And Chemicals, Inc. | Quinolinone derivative formulation and its production method |
| US20030119826A1 (en) | 2001-09-24 | 2003-06-26 | Pharmacia Corporation | Neuroprotective treatment methods using selective iNOS inhibitors |
| US6875869B2 (en) | 2002-06-12 | 2005-04-05 | Active Biotech Ab | Process for the manufacture of quinoline derivatives |
| SE0201778D0 (sv) | 2002-06-12 | 2002-06-12 | Active Biotech Ab | Process for the manufacture of quinoline derivatives |
| US7560557B2 (en) | 2002-06-12 | 2009-07-14 | Active Biotech Ag | Process for the manufacture of quinoline derivatives |
| US20060193789A1 (en) * | 2002-10-25 | 2006-08-31 | Foamix Ltd. | Film forming foamable composition |
| US20070292461A1 (en) | 2003-08-04 | 2007-12-20 | Foamix Ltd. | Oleaginous pharmaceutical and cosmetic foam |
| US7820145B2 (en) | 2003-08-04 | 2010-10-26 | Foamix Ltd. | Oleaginous pharmaceutical and cosmetic foam |
| US7790197B2 (en) | 2003-06-09 | 2010-09-07 | Warner-Lambert Company Llc | Pharmaceutical compositions of atorvastatin |
| US20050271717A1 (en) | 2003-06-12 | 2005-12-08 | Alfred Berchielli | Pharmaceutical compositions of atorvastatin |
| US20050074451A1 (en) | 2003-06-25 | 2005-04-07 | Elan Pharmaceuticals, Inc. | Methods and compositions for treating rheumatoid arthritis |
| US8795693B2 (en) | 2003-08-04 | 2014-08-05 | Foamix Ltd. | Compositions with modulating agents |
| US8314124B2 (en) | 2004-02-06 | 2012-11-20 | Active Biotech Ab | Crystalline salts of quinoline compounds and methods for preparing them |
| SE0400235D0 (sv) | 2004-02-06 | 2004-02-06 | Active Biotech Ab | New composition containing quinoline compounds |
| AU2005231467A1 (en) | 2004-04-01 | 2005-10-20 | Elan Pharmaceuticals, Inc. | Steroid sparing agents and methods of using same |
| CA2579038A1 (en) | 2004-09-02 | 2006-03-16 | Teva Pharmaceutical Industries, Ltd. | Combination therapy with glatiramer acetate and n-acetylcysteine for the treatment of multiple sclerosis |
| HRP20160455T1 (hr) | 2004-09-09 | 2016-07-15 | Yeda Research And Development Co., Ltd. | Smjese polipeptida, sastavi koji ih sadrže i postupci za njihovu pripremu, te njihove primjene |
| US20060205822A1 (en) | 2004-12-22 | 2006-09-14 | Forest Laboratories, Inc. | 1-Aminocyclohexane derivatives for the treatment of multiple sclerosis, emotional lability and pseudobulbar affect |
| US9168286B2 (en) | 2005-10-13 | 2015-10-27 | Human Genome Sciences, Inc. | Methods and compositions for use in treatment of patients with autoantibody positive disease |
| KR20080074120A (ko) | 2005-10-13 | 2008-08-12 | 휴먼 게놈 사이언시즈, 인코포레이티드 | 자가항체 양성 질환 환자의 치료에 유용한 방법 및 조성물 |
| BRPI0617477A2 (pt) | 2005-10-19 | 2011-07-26 | Teva Pharma | mistura de partÍculas cristalinas de laquinimod sàdica, composiÇço, processo de cristalizaÇço de laquinimod sàdica, laquinimod sàdica, e, processo para produzir uma composiÇço farmacÊutica |
| AU2006307939B2 (en) | 2005-10-26 | 2012-03-29 | Merck Serono Sa | Sulfonamide derivatives and use thereof for the modulation of metalloproteinases |
| US20080108641A1 (en) | 2006-02-08 | 2008-05-08 | Ajami Alfred M | Compounds for treating inflammatory disorders, demyelinating disdorders and cancers |
| US8367629B2 (en) | 2006-02-14 | 2013-02-05 | Noxxon Pharma Ag | MCP-1 binding nucleic acids and use thereof |
| US8410115B2 (en) | 2006-02-28 | 2013-04-02 | Elan Pharmaceuticals, Inc. | Methods of treating inflammatory and autoimmune diseases with alpha-4 inhibitory compounds |
| HUE047230T2 (hu) | 2006-02-28 | 2020-04-28 | Biogen Ma Inc | Gyulladásos és autoimmun betegségek natalizumabbal való kezelésének módszerei |
| KR20080104343A (ko) | 2006-03-03 | 2008-12-02 | 엘란 파마슈티칼스, 인크. | 나탈리주마브로 염증 및 자가면역 질환을 치료하는 방법 |
| US9399061B2 (en) | 2006-04-10 | 2016-07-26 | Abbvie Biotechnology Ltd | Methods for determining efficacy of TNF-α inhibitors for treatment of rheumatoid arthritis |
| CN101466379B (zh) * | 2006-06-12 | 2012-10-31 | 泰华制药工业有限公司 | 稳定的拉喹莫德的制剂 |
| WO2007146331A1 (en) | 2006-06-12 | 2007-12-21 | Teva Pharmaceutical Industries, Ltd. | Tannate salt form of polypeptide mixtures, their preparation and use |
| ATE510538T1 (de) | 2006-08-11 | 2011-06-15 | Univ Johns Hopkins | Zusammensetzungen und verfahren für nervenschutz |
| BRPI0715950A2 (pt) | 2006-08-17 | 2013-07-30 | Univ Chicago | tratamento de doenÇas inflamatàrias |
| AU2007338771A1 (en) | 2006-12-19 | 2008-07-03 | Merrimack Pharmaceuticals, Inc. | Coadministration of alpha-fetoprotein and an immunomodulatory agent to treat multiple sclerosis |
| CA2693697C (en) | 2007-07-11 | 2017-07-25 | Medicinova, Inc. | Treatment of progressive neurodegenerative disease with ibudilast |
| US20100260716A1 (en) * | 2007-10-23 | 2010-10-14 | Ucb Pharma Gmbh | Compounds for treating demyelination conditions |
| WO2009082471A1 (en) | 2007-12-20 | 2009-07-02 | Teva Pharmaceutical Industries, Ltd. | Stable laquinimod preparations |
| ES2329327B1 (es) * | 2008-03-19 | 2010-09-17 | Proyecto De Biomedicina Cima, S.L. | Combinaciones sinergicas de 5'-metiltioadenosina. |
| AU2009288108B2 (en) | 2008-09-03 | 2013-10-17 | Teva Pharmaceutical Industries, Ltd. | 2-oxo-1,2-dihydro-quinoline modulators of immune function |
| AR073295A1 (es) | 2008-09-16 | 2010-10-28 | Genentech Inc | Metodos para tratar la esclerosis multiple progresiva. articulo de fabricacion. |
| EP2355660A4 (en) | 2008-10-13 | 2012-05-02 | Biovista Inc | COMPOSITIONS AND METHODS FOR THE TREATMENT OF MULTIPLE SCLEROSIS |
| AU2009313927A1 (en) | 2008-11-13 | 2010-05-20 | Astrazeneca Ab | Azaquinolinone derivatives and uses thereof |
| WO2010070449A2 (en) | 2008-12-17 | 2010-06-24 | Actavis Group Ptc Ehf | Highly pure laquinimod or a pharmaceutically acceptable salt thereof |
| KR101083247B1 (ko) * | 2009-06-05 | 2011-11-14 | 중앙대학교 산학협력단 | Ｆｔｙ720을 유효성분으로 포함하는 미백용 조성물 |
| NZ597378A (en) * | 2009-06-19 | 2014-08-29 | Teva Pharma | Treatment of multiple sclerosis with laquinimod |
| BR112012002124A2 (pt) | 2009-07-30 | 2015-09-15 | Teva Pharma | tratamento da doença de crohn com laquinimode. |
| WO2011019375A1 (en) | 2009-08-10 | 2011-02-17 | Teva Pharmaceutical Industries Ltd. | Treatment of bdnf-related disorders using laquinimod |
| EP3831371A1 (en) * | 2009-09-29 | 2021-06-09 | Novartis AG | Dosage regimen of an s1p receptor modulator |
| WO2011086470A1 (en) | 2010-01-13 | 2011-07-21 | Ramot At Tel-Aviv University Ltd | Treatment of multiple sclerosis |
| EA201290860A1 (ru) | 2010-03-03 | 2013-04-30 | Тева Фармасьютикал Индастриз Лтд. | Лечение ревматоидного артрита комбинацией лаквинимода и метотрексата |
| KR20130006640A (ko) | 2010-03-03 | 2013-01-17 | 테바 파마슈티컬 인더스트리즈 리미티드 | 라퀴니모드를 이용한 루푸스 신장염의 치료 |
| US20110217295A1 (en) | 2010-03-03 | 2011-09-08 | Asi Haviv | Treatment of lupus arthritis using laquinimod |
| AU2011274496B2 (en) | 2010-07-09 | 2016-03-10 | Teva Pharmaceutical Industries Ltd. | Deuterated N-ethyl-N-phenyl-1,2-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide, salts and uses thereof |
| JP5934202B2 (ja) | 2010-07-09 | 2016-06-15 | テバ ファーマシューティカル インダストリーズ リミティド | ５−クロロ−４−ヒドロキシ−１−メチル−２−オキソ−ｎ−フェニル−１，２−ジヒドロキノリン−３−カルボキサミドと、その塩及びその使用 |
| PE20140872A1 (es) | 2010-12-07 | 2014-08-09 | Teva Pharma | Uso de laquinimod para reducir la fatiga, mejorar el estado funcional y mejorar la calidad de vida en pacientes con esclerosis multiple |
| HK1198278A1 (en) | 2011-07-28 | 2015-03-27 | Teva Pharmaceutical Industries Ltd. | Treatment of multiple sclerosis with combination of laquinimod and interferon-beta |
| SG10201606191PA (en) | 2011-07-28 | 2016-09-29 | Teva Pharma | Treatment of multiple sclerosis with combination of laquinimod and glatiramer acetate |
| SG11201401330YA (en) * | 2011-10-12 | 2014-05-29 | Teva Pharma | Treatment of multiple sclerosis with combination of laquinimod and fingolimod |
| WO2013116657A1 (en) | 2012-02-03 | 2013-08-08 | Teva Pharmaceutical Industries Ltd. | USE OF LAQUINIMOD FOR TREATING CROHN'S DISEASE PATIENTS WHO FAILED FIRST-LINE ANTI-TNFα THERAPY |
| MX2014009889A (es) | 2012-02-16 | 2014-11-13 | Teva Pharma | N-etil-n-fenil-1,2-dihidro-4,5-di-hidroxi-1-metil-2-oxo-3-quinoli ncarboxamida, preparacion y usos de los mismos. |
| US20130259856A1 (en) | 2012-03-27 | 2013-10-03 | Teva Pharmaceutical Industries, Ltd. | Treatment of multiple sclerosis with combination of laquinimod and dimethyl fumarate |
| TW201804997A (zh) | 2012-05-02 | 2018-02-16 | 以色列商泰瓦藥品工業有限公司 | 高劑量拉喹莫德(laquinimod)於治療多發性硬化症之用途 |
-
2012
- 2012-10-11 SG SG11201401330YA patent/SG11201401330YA/en unknown
- 2012-10-11 HK HK15100287.5A patent/HK1199820A1/xx unknown
- 2012-10-11 JP JP2014535874A patent/JP2014530821A/ja not_active Withdrawn
- 2012-10-11 WO PCT/US2012/059733 patent/WO2013055907A1/en not_active Ceased
- 2012-10-11 CN CN201280057918.9A patent/CN103974704A/zh active Pending
- 2012-10-11 AU AU2012322706A patent/AU2012322706A1/en not_active Abandoned
- 2012-10-11 EA EA201490748A patent/EA201490748A1/ru unknown
- 2012-10-11 EP EP12840715.2A patent/EP2766020A4/en not_active Withdrawn
- 2012-10-11 KR KR1020147012601A patent/KR20140101333A/ko not_active Withdrawn
- 2012-10-11 MX MX2014004420A patent/MX2014004420A/es unknown
- 2012-10-11 CA CA2851525A patent/CA2851525A1/en not_active Abandoned
- 2012-10-11 US US13/650,060 patent/US8889627B2/en not_active Expired - Fee Related
- 2012-10-11 CN CN201610629442.1A patent/CN106344576A/zh active Pending
- 2012-10-11 BR BR112014008731A patent/BR112014008731A2/pt not_active IP Right Cessation
- 2012-10-12 TW TW101137835A patent/TW201321001A/zh unknown
- 2012-10-12 AR ARP120103829A patent/AR088458A1/es unknown
- 2012-10-12 UY UY0001034395A patent/UY34395A/es not_active Application Discontinuation
-
2014
- 2014-03-26 IL IL231724A patent/IL231724A0/en unknown
- 2014-05-12 ZA ZA2014/03378A patent/ZA201403378B/en unknown
- 2014-10-21 US US14/520,145 patent/US20150037263A1/en not_active Abandoned
-
2016
- 2016-06-10 US US15/179,800 patent/US20160279118A1/en not_active Abandoned
-
2017
- 2017-01-18 JP JP2017006394A patent/JP2017137298A/ja active Pending
- 2017-07-31 US US15/665,061 patent/US20170333418A1/en not_active Abandoned
- 2017-08-09 AU AU2017213497A patent/AU2017213497A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP2017137298A (ja) | 2017-08-10 |
| WO2013055907A1 (en) | 2013-04-18 |
| US20170333418A1 (en) | 2017-11-23 |
| UY34395A (es) | 2013-05-31 |
| EP2766020A4 (en) | 2015-04-01 |
| IL231724A0 (en) | 2014-05-28 |
| JP2014530821A (ja) | 2014-11-20 |
| ZA201403378B (en) | 2015-07-29 |
| CN103974704A (zh) | 2014-08-06 |
| US20160279118A1 (en) | 2016-09-29 |
| US20130096158A1 (en) | 2013-04-18 |
| EA201490748A1 (ru) | 2014-12-30 |
| TW201321001A (zh) | 2013-06-01 |
| AU2017213497A1 (en) | 2017-08-31 |
| MX2014004420A (es) | 2014-07-09 |
| CN106344576A (zh) | 2017-01-25 |
| EP2766020A1 (en) | 2014-08-20 |
| US20150037263A1 (en) | 2015-02-05 |
| KR20140101333A (ko) | 2014-08-19 |
| US8889627B2 (en) | 2014-11-18 |
| AU2012322706A1 (en) | 2014-05-22 |
| HK1199820A1 (en) | 2015-07-24 |
| AR088458A1 (es) | 2014-06-11 |
| BR112014008731A2 (pt) | 2017-04-25 |
| CA2851525A1 (en) | 2013-04-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201403378B (en) | Treatment of multiple sclerosis with combination of laquinimod and fingolimod | |
| IL266582A (en) | Preparations and methods for the treatment of hemoglobin diseases | |
| ZA201407722B (en) | Treatment of multiple sclerosis with combination of laquinimod and dimethyl fumarate | |
| IL251397A0 (en) | Treatment of multiple sclerosis by administering a combination of laquinimod and glatiramer acetate | |
| IL252699A0 (en) | Use of lequinimod to treat multiple sclerosis | |
| ZA201401217B (en) | Treatment of multiple sclerosis with combination of laquinimod and interferon-beta | |
| ZA201502503B (en) | Hppd variants and methods of use | |
| ZA201401653B (en) | Pyrazol-4yl-heterocyclyl-carboxamide compounds and methods of use | |
| SG10201707020TA (en) | Substituted 3-haloallylamine inhibitors of ssao and uses thereof | |
| EP2675471A4 (en) | HSA-RELATED COMPOSITIONS AND USE PROCESSES | |
| EP2709999A4 (en) | CHINAZOLIN-7-ETHER COMPOUNDS AND ITS APPLICATION | |
| EP2844255A4 (en) | USE OF HIGH DOSE LAQUINIMOD FOR THE TREATMENT OF MULTIPLE SCLEROSIS | |
| GB201103293D0 (en) | Treatment and prevention of malaria | |
| EP2670438A4 (en) | SELECTION AND TREATMENT OF PATIENTS | |
| ZA201408062B (en) | Compositions and methods for the treatment of multiple sclerosis | |
| ZA201307058B (en) | Use of polyaminoisoprenyl derrivatives in antobiotic or antisertic treatment | |
| ZA201408058B (en) | Compositions and methods for the treatment of epilepsy | |
| ZA201405829B (en) | Cleaning arrangement and method of use | |
| GB201117252D0 (en) | Improved treatment of hard surfaces | |
| GB201104632D0 (en) | Use of medicament |